2-(3-methylphenyl)-N-[4-(2-methylpyridin-4-yl)phenyl]hexanamide | 1161356-04-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(3-methylphenyl)-N-[4-(2-methylpyridin-4-yl)phenyl]hexanamide
• CAS: 1161356-04-2
• 化学式: C₂₅H₂₈N₂O
• 分子量: 372.51
• InChiKey: ALKKVGUCPPVDBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-溴-2-甲基吡啶 在 potassium dihydrogenphosphate 、 四(三苯基膦)钯 、 [(4-(N,N-二甲氨基)苯基]二叔丁基膦 、 sodium carbonate 、 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 1.0h， 生成 2-(3-methylphenyl)-N-[4-(2-methylpyridin-4-yl)phenyl]hexanamide
  参考文献：
  名称：

  Discovery of 2-methylpyridine-based biaryl amides as γ-secretase modulators for the treatment of Alzheimer’s disease

  摘要：

  gamma-Secretase modulators (GSMs) are potentially disease-modifying treatments for Alzheimer's disease. They selectively lower pathogenic A beta 42 levels by shifting the enzyme cleavage sites without inhibiting gamma-secretase activity, possibly avoiding known adverse effects observed with complete inhibition of the enzyme complex. A cell-based HTS effort identified the sulfonamide 1 as a GSM lead. Lead optimization studies identified compound 25 with improved cell potency, PKDM properties, and it lowered A beta 42 levels in the cerebrospinal fluid ( CSF) of Sprague-Dawley rats following oral administration. Further optimization of 25 to improve cellular potency is described. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.09.041

文献信息

• Gamma Secretase Modulators
  申请人：Hitchcock Stephen A.

  公开号：US20110166132A1

  公开（公告）日：2011-07-07

  The present invention provides compounds that are gamma secretase modulators and are therefore useful for the treatment of diseases treatable by modulation of gamma secretase such as Alzheimer's disease. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明提供的化合物是伽马分泌酶调节剂，因此可用于治疗可通过伽马分泌酶调节治疗的疾病，例如阿尔茨海默病。还提供了包含这些化合物的药物组合物以及制备这些化合物的过程。
• Discovery of 2-methylpyridine-based biaryl amides as γ-secretase modulators for the treatment of Alzheimer’s disease
  作者：Jian Jeffrey Chen、Wenyuan Qian、Kaustav Biswas、Chester Yuan、Albert Amegadzie、Qingyian Liu、Thomas Nixey、Joe Zhu、Mqhele Ncube、Robert M. Rzasa、Frank Chavez、Ning Chen、Frenel DeMorin、Shannon Rumfelt、Christopher M. Tegley、Jennifer R. Allen、Stephen Hitchcock、Randy Hungate、Michael D. Bartberger、Leeanne Zalameda、Yichin Liu、John D. McCarter、Jianhua Zhang、Li Zhu、Safura Babu-Khan、Yi Luo、Jodi Bradley、Paul H. Wen、Darren L. Reid、Frank Koegler、Charles Dean、Dean Hickman、Tiffany L. Correll、Toni Williamson、Stephen Wood

  DOI：10.1016/j.bmcl.2013.09.041

  日期：2013.12

  gamma-Secretase modulators (GSMs) are potentially disease-modifying treatments for Alzheimer's disease. They selectively lower pathogenic A beta 42 levels by shifting the enzyme cleavage sites without inhibiting gamma-secretase activity, possibly avoiding known adverse effects observed with complete inhibition of the enzyme complex. A cell-based HTS effort identified the sulfonamide 1 as a GSM lead. Lead optimization studies identified compound 25 with improved cell potency, PKDM properties, and it lowered A beta 42 levels in the cerebrospinal fluid ( CSF) of Sprague-Dawley rats following oral administration. Further optimization of 25 to improve cellular potency is described. (C) 2013 Elsevier Ltd. All rights reserved.